Abstract
The absorption, disposition and metabolism of levetiracetam, a new antiepileptic drug, have been investigated after a single oral dose of the 14C-labelled molecule administered to male healthy volunteers. As chiral inversion can occur during drug metabolism, the chiral inversion of levetiracetam and/or of its major metabolite produced by hydrolysis (the corresponding acid) was also investigated. Finally, the in vitro hydrolysis of levetiracetam to its major metabolite and the inhibition of this reaction in human blood have been studied. Levetiracetam was very rapidly absorbed in man, with the peak plasma concentration of the unchanged drug occurring at 0.25–0.50 h. The unchanged drug accounted for a very high percentage of plasma radioactivity (97–82%) at all the times measured, i.e. until 48 h after administration. The apparent volume of distribution of the compound was close (0.55–0.62 l/kg) to the volume of total body water. Total body clearance (0.80–0.97 ml/min/kg) was much lower than the nominal hepatic blood flow. The plasma elimination half-life of the unchanged drug varied between 7.4 h and 7.9 h. Plasma to blood ratio of total radioactivity concentrations was 1.1–1.3, showing that radioactivity concentrations were similar in blood cells and plasma. The balance of excretion was very high in all four volunteers. The predominant route of excretion was via urine, accounting for a mean of 95% of the administered dose after 4 days. Two major radioactive components were present in urine, the unchanged drug and the acid obtained by hydrolysis, accounting for 66% and 24% of the dose after 48 h, respectively. Hydrolysis of levetiracetam in human blood followed Michaelis-Menten kinetics with Km and Vmax values of 435 µM and 129 pmol/min/ml blood, respectively. Among the inhibitory agents investigated in this study, only paraoxon inhibited levetiracetam hydrolysis (92% inhibition at 100 µM). Oxidative metabolism occurred in man, although it accounted for no more than 2.5% of the dose. There was no evidence of chiral inversion.
Similar content being viewed by others
References
Perucca E (1996) The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 42:531–543
Perucca E, Bialer M (1996) The clinical pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokin 31:29–46
Riva R, Albani F, Contin L, Baruzzi A (1996) Pharmacokinetic interactions between antiepileptic drugs. Clin Pharmacol 31:470–493
Roche C (1999) Qu’apportent les nouveaux antiepileptiques? Impact Médecin Hebdo 454:41–42
Strolin Benedetti M (2000) Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fund Clin Pharmacol 14:301–319
Gatti G, Bonami I, Jannuzzi G, Perucca E (2000) The new antiepileptic drugs: pharamacological and clinical aspects. Curr Pharm Des 6:839–860
Lloyd P, Flesch G, Dieterle W (1994) Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 35:S10-S13
Stables J, Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E (1995) Progress report on new antiepileptic drugs: a summary of the 2nd Eilat Conference. Epilepsy Res 22:235–246
Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E (1996) Progress report on new antiepileptic drugs: a summary of the 3rd Eilat Conference. Epilepsy Res 25:299–319
Löscher W (1998) New visions in the pharmacology of anticonvulsion. Eur J Pharmacol 342:1–13
Shorvon SD, van Rijckevorsel K (2002) A new antiepileptic drug—Levetiracetam, a pyrrolidone recently licensed as an antiepileptic drug. J Neurol Neurosurg Psychiatry 72:426–428
Patsalos PN, Walker MC, Ratnaraj N, Sander JWAS, Shorvon SD (1995) The pharmacokinetics of levetiracetam (ucb L059) in patients with intractable epilepsy (abstract). Epilepsia 36:54
Edelbroeck PM, de Wilde-Ockeleon JM, Kastelejin-Nolste-Trenite DGA, Alpherts WCJ, Meijer JWA (1993) Evaluation of the pharmacokinetics and neuropsychometrics parameters in chronic comedicated epileptic patients of three increasing dosages of a novel antiepileptic drug, ucb LO59 250 mg capsules per each dose for one week followed by two weeks of placebo (abstract). Epilepsia 34:7
Caldwell J, Hutt AJ, Fournel-Gigleux S (1988) The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences. Biochem Pharmacol 37:105–114
Wechter WJ, Loughead DG, Reischer RJ, Van-Giessen GJ, Kaiser DG (1974) Enzymatic inversion at saturated carbon: nature and mechanism of the inversion of (−)R-p-iso-butyl hydratropic acid. Biochem Biophys Res Commun 61:833–837
Kaiser DG, Van-Giessen GJ, Reischer RJ, WecherWS (1976) Isomeric inversion of ibuprofen (R)-enantiomer in humans. J Pharm Sci 65:269–273
Lee EJD, Williams K, Day R, Graham G, Champion D (1985) Stereoselective disposition of ibuprofen enantiomers in man. Br J Clin Pharmacol 19:669–674
Nakamura Y, Yamaguchi T, Hashimoto S, Ikatani S,Nakagawa Y (1981) Optical isomerization mechanism of(−)R-hydratropic acid derivatives. J Pharmacobiol Dyn 4:51
Naitoh T, Kawaguchi S, Kakiki M, Ohe H, Kajiwara A, Horie T (1998) Species differences and mechanism of the epimerization of a new MAO-A inhibitor. Xenobiotica 28:269–280
Madhu C, Duff S, Baumgarten V, Rix P, Small D, Tang-Liu D (1997) Metabolic deesterification of tazorotene in human blood and rat and human liver microsomes. J Pharmaceut Sci 86:972–974
Nishigaki I, Itoh T, Ogasawara N (1983) Quantitative variations in polymorphic types of human red cell esterase D. Ann Hum Genet 47:187–192
Trundle D, Marcial G, (1988) Detection of cholinesterase inhibition. The significance of cholinesterase measurements. Ann Clin Lab Sci 18:345–352
Maghoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet September 17:584–586
Nicolas J-M, Collart P, Gerin B, Mather G, Trager W, Levy R, Roba J, (1998) Levetiracetam: in vitro metabolism assays and prediction of drug-drug interaction. In: Boobis AR, Kremers P, Pelkonen O, Pithan K (eds) Proceedings, European symposium on the prediction of drug metabolism in man: progress and problems. 19–20 May 1998, Liège (Belgium), pp 193–195
Wagner JG (1975) Fundamentals of clinical pharmacokinetics, 1st edn. Drug Intelligence Publications, Inc., Hamilton, Illinois, pp 57–128
Rowland M, Tozer TN (1995) Estimation of elimination half-life from urine data. In: Clinical pharmacokinetics—concepts and applications, 3rd edn. Williams and Wilkins Media, Pa., pp 473–477
Perucca E, Grimaldi R, Frigo GM, Sardi A, Mönig H, Ohnhaus EE (1988) Comparative effects of rifabutin and rifampicin in normal subjects. Eur J Clin Pharmacol 34:595–599
Teunissen MWE, Bakker W, Meerburg-van der Torren JE, Breimer DD (1984) Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis. Br J Clin Pharmac 18:701–706
Anderson GD (1998) A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 32:554–563
Kerr BM, Rettie AE, Eddy AC, Loiseau P, Guyot M, Wilensky AJ, Levy RH (1989) Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation. Clin Pharmacol Ther 46:82–93
Wen X, Wang JS, Kivistö KT, Neuvonen PJ, Backman JT (2001) In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome-P450 2C9 (CYP2C9). Br J Clin Pharmacol 52:547–553
Robbins DK, Wedlund PJ, Elsberg S, Oesch F, Thomas H (1992) Interaction of valproic acid and some analogues with microsomal epoxide hydrolase. Biochem Pharmacol 43:775–783
Facciolà G, Avenoso A, Scordo MG, Madia AG, Ventimiglia A., Perucca E, Spina E (1999) Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monitoring 21:341–345
Lai ML, Huang JD (1993) Dual effect of valproic acid on the pharmacokinetics of phenytoin. Biopharmaceut Dispos 14:365–370
Tanaka E (1999) Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther 24:87–92
Minagawa T, Kohno Y, Suwa T, Tsuji A (1995) Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases. Biochem Pharmacol 49:1361–1365
Kao YJ, Tellez J,Turner DR (1990) Dose-dependent effect of metoclopramide on cholinesterases and suxamethonium metabolism. Br J Anaesth 65:220–224
Jensen FS, Skovgaard LT, Viby-Mogensen J (1995) Identification of human plasma cholinesterase variants in 6,688 individuals using biochemical analysis. Acta Anaesthesiol Scand 39:157–162
Slatter JG, Su P, Sams JP, Schaff LJ, Wienkers LC (1997) Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potiential drug interactions. Drug Metab Dispos 25:1157–1164
Maren TH (1977) Use of inhibitors in physiological studies of carbonic anhydrase. Am J Physiol 232:F291–F297
Matsumoto K, Miyazaki H, Fujii T, Hashimoto M (1989) Binding of sulfonamides to erythrocytes and their components. Chem Pharm Bull 37:1913–1915
Masereel B, Rolin S, Abbate F, Scozzafava A, Supuran CT (2002) Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem 45:312–320
Calvo R, Carlos R, Errill S (1980) Effects of disease and acetasolamide on procaine hydrolysis by red blood cells enzymes. Clin Pharmacol Ther 27:179–183
Williams FM, Clinical significance of esterases in man (1985) Clin Pharmacokin 10:392–403
Rowland M, Tozer TN (1995) Intravenous dose. In: Clinical pharmacokinetics—concepts and applications, 3rd edn. Williams and Wilkins Media, Pa., pp 18–33
Rowland M, Tozer TN (1995) Elimination. In: Clinical pharmacokinetics—Concepts and applications, 3rd edn. Williams and Wilkins Media, Pa., pp 156–183
Bourgeois BFD (1995) Important pharmacokinetic properties of antiepileptic drugs. Epilepsia 36:S1–S7
Testa B (1995) Monooxygenase catalysed N-C cleavage. In: The metabolism of drugs and other xenobiotics—biochemistry of Redox reactions. Testa B, Caldwell J (eds), Academic Press limited, London, pp 215–224
Gower AJ, Noyer M, Verloes R, Gobert J., Wülfert E (1992) ucb L059, a novel anticonvulsant drug: pharmacological profile in animals. Eur J Pharmacol 222:193
Noyer M, Gillard M, Matagne A, Hénichart JP, Wülfert E (1995) The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 286:137–146
Eichelbaum M, Gross A (1991) Implications of stereoselectivity in clinical pharmacokinetics. In: New trends in pharmacokinetics, Rescigno A Thakur AK (eds), NATO ASI Series, Series A: Life Sci 221, Plenum Press, New York, pp 271–279
Beydoun A, Uthman BM, Sackellares JC (1995) Gabapentin: pharmacokinetics, efficacy and safety. Clin Neuropharmacol 18:469–481
Elwes RDC, Binnie CD (1996) Clinical pharmacokinetics of newer antiepileptic drugs: lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin Pharmacokin 30:403–415
Van Wieringen A, Meijer JWA, Van Emde Boas W, Vermeij TAC (1990) Pilot study to determine the interaction of oxyracetam with antiepileptic drugs. Clin Pharmacokinet 18:332–338
Perucca E, Gidal BE, Ledent E, Baltes E (2000) Levetiracetam does not interact with other antiepileptic drugs. Epilepsia 41:L08 (Proceedings Annual Meeting of the American Epilepsy Society, Los Angeles, USA, December 2000)
Browne TR, Szabo GK, Leppik IE, Josephs E, Paz J, Baltes E, Jensen CM (2000) Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin determined by new technique. J Clin Pharmacol 40:590–595
Klitgaard H, Matagne A, Gobert J, Wuelfert E. (1998) Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353:191–206
Jamis-Dow CA, Katki AG, Collins JM, Klecker RW (1997) Rifampicin and rifabutin and their metabolism by human liver esterases. Xenobiotica 27:1015–1024
Khanna P, Gupta MB, Gupta GP, Sanwal GG, Ali B (1991) Influence of chronic oral intake of cannabis extract on oxidative and hydrolytic metabolism of xenobiotics in rat. Biochem Pharmacol 41:109–113
Khanna P, Kaur S, Sanwal GG and Ali B (1991) Characteristics of a cytosolic arylacylamidase metabolizing thiacetazone. J Pharmacol Exper Ther 262:1225–1231
Kaur S, Ali B (1983) The effects of phenobarbital, 3-methylcholanthrene and benzo(a)pyrene on the hydrolysis of xenobiotics in the rat. Biochem Pharmacol 32:3479–3480
Satoh T, Moroi K (1977) Effect of pretreatment with tricresylphosphates and phenobarbital on the metabolism and toxicity of procaine in rats. Jpn J Pharmacol 27:233–237
Schwark WS, Ecobichon DJ (1968) Subcellular localization and drug-induced changes of rat liver and kidneys esterases. Can J Physiol Pharmacol 46:207–212
Siddiqui A, Srivastava SP, Ali B (1990) Effect of mancozeb on hydrolytic metabolism of xenobiotics. Res Commun Chem Pathol Pharmacol 70:249–252
Nousiainen U, Hänninen O (1981) On the inducibility of cytosolic and microsomal carboxylesterase by phenobarbital in rat tissues. Acta Pharmacol Toxicol 49:77–80
Nousiainen U, Törrönen R, Hänninen O (1984) Differential induction of various carboxylesterases by certain polycyclic aromatic hydrocarbons in the rat. Toxicology 32:243–251
Puche E, Garcia de la Serrana H, Mota C, Sazucedo R (1989) Serum aspirin-esterase activity in epileptic patients receiving treatment with phenobarbital, phenytoin, carbamazepine and valproic acid. Int J Clin Pharmacol Res 9:55–58
Reife RA (1998) Assessing pharmacokinetic and pharmacodynamic interactions in clinical trials of antiepileptic drugs. Antiepil drug Dev Adv Neurol 76:95–103
Acknowledgement
The authors wish to thank B. Kenda and M. Plisnier for helpful discussion on the structures of reference standards and metabolites, C. Doumergue for documentation and M. Rovei for preparation of the manuscript. The experiments comply with the current laws of the country in which the experiments were performed.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Strolin Benedetti, M., Whomsley, R., Nicolas, JM. et al. Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur J Clin Pharmacol 59, 621–630 (2003). https://doi.org/10.1007/s00228-003-0655-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-003-0655-6